Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 6, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The FDA took a handful of actions in December 2022, including greenlighting several new clinical tools, a Type A Meeting request, and a trial recruitment pause, among others. Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.
A panel of experts in dementia discusses the latest progress in the treatment of Alzheimer disease, and the various therapies that have progressed through the pipeline. The NeurologyLive® series panel features Marwan Sabbagh, MD; Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; and Eric McDade, DO.
In the latest edition of our in-depth Q&A series, the director of the Montefiore Einstein Center for the Aging Brain provided perspective on a new study assessing the use of a novel tool aimed to confirm patients’ cognitive complaints and issues with mobility.
The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease and the new ways to approach prevention at the Clinical Trials in Alzheimer Disease conference. [WATCH TIME: 4 minutes]
The professor of neurology at the University of Toronto spoke at the 2022 American Epilepsy Society Annual Meeting about genetic approaches to comorbidities for patients with epilepsy. [WATCH TIME: 5 minutes]
Nominations for Giants of Multiple Sclerosis® are open! This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in multiple sclerosis. Nominations close on January 31, 2023!